Qual é o preço para Freeline Therapeutics Holdings plc (FRLN)

O preço para Freeline Therapeutics Holdings plc (FRLN) é $6.48

Qual é a capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN)

A capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN) é $15.41M

Histórico de Preços de Freeline Therapeutics Holdings plc (FRLN)

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Ano	Desempenho
2024	1.37%
2023	-20.74%
2022	-75.54%
2021	-87.40%
2020	0.00%

Ano

Desempenho

2024

1.37%

2023

-20.74%

2022

-75.54%

2021

-87.40%

2020

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$527.89	35.40%	US
Argenx SE ARGX.US	$996.61	50.70%	NL
CSL Limited CSL.AX	$111.31	-36.83%	AU
Lonza Group AG LONN.SW	$735.86	6.87%	CH
UCB S.A. UCB.BR	$257.75	13.01%	BE

Empresa

Preço da ação

Variação 1a%

País